News about Clinical Trials

ENTYVIO Trial Shows Disease Clearance Benefits in Ulcerative Colitis

The first Ulcerative Colitis treat-to-target trial shows ENTYVIO (vedolizumab) delays disease-related complications with disease clearance versus symptomatic remission.

Clinical Trials | 22/10/2026 | By News Bureau

GSK Reveals First Global Ris-Rez Data in Small Cell Lung Cancer

GSK has reported first global Ris-Rez data in ES-SCLC, with a 61 percent response rate in a phase 1b trial supporting further clinical development.

Clinical Trials | 22/10/2026 | By News Bureau

Tiziana Doses Last Patient in Phase 2 Trial of Foralumab

Tiziana has dosed the last patient in its phase 2 trial of intranasal foralumab for mild Alzheimer’s, evaluating monotherapy and combinations with lecanemab or donanemab.

Clinical Trials | 19/10/2026 | By News Bureau

Vividion Initiates Phase 2 Trial of VVD-214 in Advanced Colorectal Cancer

Vividion Therapeutics doses the first patient in a Phase 2 trial evaluating VVD-214 in combination with pembrolizumab for advanced colorectal cancer.

Clinical Trials | 16/10/2026 | By News Bureau

Arrowhead Reports Interim Phase 1/2a Data for ARO-MAPT

Arrowhead Pharmaceuticals has reported interim phase 1/2a ARO-MAPT data showing deep, durable tau reductions in healthy volunteers.

Clinical Trials | 15/10/2026 | By News Bureau

Bristol Myers Squibb Reports Positive RYZ101 Phase 3 Results

Bristol Myers Squibb reports positive interim results from the Phase 3 ACTION-1 trial of investigational radiopharmaceutical therapy RYZ101 in patients with GEP-NETs.

Clinical Trials | 14/10/2026 | By News Bureau

Uganda Launches Phase I Trial of Bundibugyo Ebola Vaccine

Uganda has launched a Phase I trial of Oxford’s Bundibugyo Ebola vaccine candidate, with Serum Institute of India supplying investigational doses to support clinical evaluation and global epidemic preparedness.

Clinical Trials | 14/10/2026 | By News Bureau

Orum Therapeutics Doses First Patient in ORM-1153 Trial

Orum Therapeutics has dosed the first patient in its phase 1 ORM-1153 trial for relapsed or refractory AML and other CD123-expressing blood cancers.

Clinical Trials | 14/10/2026 | By News Bureau

AbbVie Reports Phase 3 Skyrizi Data for Crohn's Disease

AbbVie has presented new phase 3 AFFIRM data showing clinical and endoscopic outcomes with subcutaneous SKYRIZI (risankizumab-rzaa) in patients Crohn's Disease.

Clinical Trials | 14/10/2026 | By News Bureau |  111

Life Biosciences Reports First Human Data for ER-100 Trial

Life Biosciences has announced first-in-human data from ongoing phase 1 trial evaluating ER-100 in optic neuropathies.

Clinical Trials | 13/10/2026 | By News Bureau